 RedHill Biopharma Ltd NASDAQ:RDHL has announced that the last patient has been enrolled in Part A of the Phase 23 study with novel, once-daily, orally-administered pill RHB-107 upamostat for non-hospitalized patients with symptomatic coronavirus COVID-19, currently being conducted in the US and South Africa. The Phase 23 study NCT04723527 with RHB-107 is aimed at evaluating treatment in patients with symptomatic COVID-19 early in the course of the disease, with a once-daily oral treatment that can be prescribed and used in the non-hospitalized patient population. 